Today’s psychedelics researchers still have to deal with the fallout of the decadeslong freeze on research. Listen to ‘The Conversation Weekly’ podcast.
Academic rigor, journalistic flair
Articles on Psychedelics research
Displaying all articles
Pinpointing the molecular targets behind the subjective effects of psychedelic drugs could help clinicians and researchers better treat psychiatric conditions.
Research shows therapeutic psilocybin to be a safe and effective antidote to end-of-life anxiety and depression. Does prohibition therefore violate our right to “life, liberty and security?”
To know the real promise of psychedelic substances like LSD, mushrooms and MDMA, researchers must embrace the principles and practise of ‘open science.’
Top contributors
-
Emeritus Professor, The National Centre for Youth Substance Use Research, The University of Queensland
-
Distinguished Professor of Neurology and Psychiatry, Director of Psychedelics Division at Neuroscape, University of California, San Francisco
-
PhD Candidate, Congnitive Neuroscience, University of Toronto
-
PhD student in Clinical Psychology, York University, Canada
-
Adjunct Professor in the School of Child & Youth Care, University of Victoria
-
Editor and Co-Host, The Conversation Weekly Podcast, The Conversation
-
Associate Science Editor & Co-Host of The Conversation Weekly Podcast, The Conversation
-
Resident in Psychiatry, SUNY Downstate Health Sciences University
-
Machine Learning Scientist at the Broad Institute of MIT &, Harvard University
-
Postdoctoral Researcher in Child Psychiatry, Vrije Universiteit Amsterdam
